On Wednesday, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)’s shares declined -3.48% to $0.0610.
AEZS offered 30.40% EPS for prior five years. The company has -246.80% return on equity value. The company has $35.33 million market capitalizations and the institutional ownership was 21.40%. Its price to book ratio was -106.64. Volatility of the stock was 30.64% for the week while for the month booked as 14.97%.
The mean estimate for the short term price target for AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) stands at $1.23 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $1.38 while the lower price target estimate is at $0.15.
Analysts mean recommendation for the stock is 2.30. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect auxiliaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned partner of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc.
WellCare Health Plans, Inc. (NYSE:WCG)’s shares dropped -9.10% to $81.11.
WCG has beta value of 1.34. The company has the market capitalization of $3.93 billion. Return on assets ratio of the company was 2.10% while its return on equity ratio was 6.00%. ATR value of company was 4.21 while stock volatility for week was 4.92% while for month was 4.63%. Debt to equity ratio of the company was -0.73.
The mean estimate for the short term price target for WellCare Health Plans, Inc. (NYSE:WCG) stands at $98.00 according to 12 Analysts. The higher price target estimate for the stock has been calculated at $120.00 while the lower price target estimate is at $84.00.
Analysts mean recommendation for the stock is 2.60. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
WellCare Health Plans, Inc. (WellCare) is a managed care company for government-sponsored health care coverage with a focus on Medicaid and Medicare programs. The Company offers a range of managed care health plans for families, children, and the aged, blind and disabled, in addition to prescription drug plans.
At the end of Wednesday’s trade, MEI Pharma Inc (NASDAQ:MEIP)‘s shares surged 14.21% to $2.09.
MEIP is currently valued at $65.51 million. The company has 34.16 million shares outstanding and 21.30% shares of the company were owned by institutional investors. The company has 1.19 value in price to book ratio. The company exchanged hands with 3.13 million shares as compared to its average daily volume of 367,735 shares. It beta stands at 0.59.
The mean estimate for the short term price target for MEI Pharma Inc (NASDAQ:MEIP) stands at $8.33 according to 3 Analysts. The higher price target estimate for the stock has been calculated at $15.00 while the lower price target estimate is at $3.00.
Analysts mean recommendation for the stock is 2.60. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates comprises Pracinostat, ME-344 and PWT143.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.